Mar. 3 at 8:45 PM
$VYGR Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028
Voyager outlined three near-term “pillars of value” — advancing two tau-directed programs, initiating two gene therapy clinical entries using blood‑brain barrier‑penetrant capsids, and expanding its NeuroShuttle brain‑delivery platform — and said it is well capitalized with cash runway into 2028.
Lead anti‑tau antibody VY7523 has completed MAD enrollment, appears safe with a CSF‑to‑serum ratio ~0.3%, and the MAD readout expected in the second half of the year is powered to assess effects on slowing pathological tau spread on PET (the company’s key endpoint).
One‑time IV gene therapy VY‑1706 is targeting 50–70% tau knockdown at a relatively low dose, with an IND planned in Q2 and first dosing expected in H2; Voyager also highlights its capsid engineering (≈30‑fold liver de‑targeting), the ALPL‑based NeuroShuttle as a differentiated BBB shuttle slated to enter the clinic this year.
